NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vivere Oncotherapies

Vivere Oncotherapies

Private
Berkeley, CaliforniaHealthcare & Life Scienceshttps://viveretx.com/

Last Round

Seed

Jan 13, 2026

Total Funding Raised

$13.21M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Vivere Oncotherapies is a biotechnology company developing targeted immunotherapies that activate the immune system to detect and destroy cancer cells in solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oncology therapeuticsoncolytic virotherapydrug discoverybiotechgene engineeringCRISPRvector engineeringcancer researchpreclinical developmentprecision medicinebiotech startuptherapeutic pipelinesolid tumor treatmentdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivere Oncotherapies Comps

Public and private peers based on sector, stage, and business model.

Vivere Oncotherapies comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vivere Oncotherapies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 13, 2026
GrantSep 5, 2025

Key People

Founding team and executive leadership

Melissa Kotterman

Chief Executive Officer, Member Board of Directors

Executive Team

Vivere Oncotherapies Investors

Notable investors and investment history

Vivere Oncotherapies investors
InvestorRounds
National Cancer InstituteSeed, Grant
California Innovation FundSeed, Pre Seed
Freeflow VenturesSeed, Pre Seed
Pillar VCSeed, Pre Seed
Berkeley Frontier FundSeed, Pre Seed
Alumni VenturesSeed
Kerna VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 8, 2026

    Grew 40% QoQ from 10 to 14 employees.

  • Feb 20, 2026

    Grew 56% QoQ, from 9 to 14 employees.

Vivere Oncotherapies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vivere Oncotherapies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivere Oncotherapies's valuation, stock price, and market status.

Firmographic Details

HeadquartersBerkeley, California
Employee Range13
Year Founded2022
Last FundingJan 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.